

Top 200 Drugs by Retail Sales in 2024

Compiled and Produced by Hayden M. Leatherwood from the Njarðarson Group (The University of Arizona)

1 Keytruda (Pembrolizumab) \$29.482 Billion Oncology	2 Eliquis (Apixaban) \$20.499 Billion Cardiology/Vascular Diseases	3 Ozempic (Semaglutide) \$16.481 Billion Diabetes	4 Dupixent (Dupilumab) \$13.557 Billion Dermatology	5 Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) \$13.423 Billion HIV/AIDS	6 Jardiance (Empagliflozin) \$12.798 Billion Diabetes	7 Skyrizi (Risankizumab) \$11.718 Billion Immunology	8 Darzalex (Daratumumab) \$11.670 Billion Oncology	9 Mounjaro (Tirzepatide) \$11.540 Billion Diabetes	10 Stelara (Ustekinumab) \$10.750 Billion Immunology	11 Trikafta (Elexacaftor/Tezacaftor/Voxlozole) \$10.238 Billion Cystic Fibrosis	12 Opdivo (Nivolumab) \$10.183 Billion Oncology	13 Eylea (Aflibercept) \$9.450 Billion Ophthalmology	14 Humira (Adalimumab) \$8.993 Billion Immunology	15 Gardasil (HPV Quadrivalent Vaccine) \$8.583 Billion Infectious Diseases	16 Farxiga (Dapagliflozin) \$8.218 Billion Diabetes	17 Wegovy (Semaglutide) \$8.068 Billion Nutritional Deficiency	18 Entresto (Sacubitril/Valsartan) \$7.822 Billion Cardiology/Vascular Diseases	19 Xtandi (Enzalutamide) \$7.802 Billion Oncology	20 Ocrevus (Ocrelizumab) \$7.429 Billion Neurology
21 Tagrisso (Osimertinib) \$6.580 Billion Oncology	22 Premiar Family (Pharmacositol Fused Conjugate) \$6.411 Billion Infectious Diseases	23 Imbruvica (Ixazumib) \$6.385 Billion Oncology	24 Cosentyx (Secukinumab) \$6.141 Billion Immunology	25 Xarelto (Rivastigmine) \$6.037 Billion Cardiology/Vascular Diseases	26 Entyvio (Vedolizumab) \$6.026 Billion Immunology	27 Rinvoq (Upadacitinib) \$5.971 Billion Immunology	28 Revlimid (Lenalidomide) \$5.809 Billion Oncology	29 Paxlovid (Nirmovir/Nirmatrelvir) \$5.716 Billion Infectious Diseases	30 Vyndugel (Erdafitinib) \$5.451 Billion Anti-Cancer and Diabetes	31 Comirnaty (COVID-19 Vaccine, mRNA) \$5.353 Billion Infectious Diseases	32 Verzenio (Abiraterone) \$5.306 Billion Oncology	33 Trulicity (Dulaglutide) \$5.253 Billion Diabetes	34 Immunoglobulin (Immunoglobulin) \$5.012 Billion Immunology	35 Hemlibra (Emicizumab) \$4.940 Billion Hematology	36 Zepbound (Tirzepatide) \$4.925 Billion Nutritional Deficiency	37 Imfinzi (Durvalumab) \$4.717 Billion Oncology	38 Prolia (Denosumab) \$4.374 Billion Musculoskeletal	39 Ibrance (Palbociclib) \$4.347 Billion Oncology	40 Xolair (Omalizumab) \$4.244 Billion Immunology
41 Ofev (Nintedanib) \$4.262 Billion Pulmonary/Respiratory Diseases	42 Vabysmo (Voretigene Tetracarboxylate) \$4.256 Billion Oncology	43 Invega Sustenna (Paliperidone Palmitate) \$4.222 Billion Neurology	44 Shingrix (Zoster Vaccine Recombinant, Adjuvanted) \$4.184 Billion Infectious Diseases	45 Tecentriq (Atezolizumab) \$4.009 Billion Oncology	46 Enbrel (Etanercept) \$4.026 Billion Immunology	47 Perjeta (Pertuzumab) \$3.983 Billion Oncology	48 Ultomiris (Eculizumab) \$3.924 Billion Neurology	49 Orencia (Alectracept) \$3.853 Billion Oncology	50 Tremfya (Ravulizumab) \$3.870 Billion Immunology	51 Enhertu (Trastuzumab Deruxtecan) \$3.856 Billion Oncology	52 Pomalyst (Pomalidomide) \$3.848 Billion Oncology	53 Trelegly Ellipta (Fluticasone Furoate/Vilanterol/Umeciclib) \$3.561 Billion Pulmonary/Respiratory Diseases	54 Botox Therapeutic (OnabotulinumtoxinA) \$3.283 Billion Oncology	55 Vraylar (Cariprazine) \$3.267 Billion Oncology	56 Taltz (Tigecycline) \$3.240 Billion Oncology	57 Rybelsus (Eliquis) \$3.229 Billion Diabetes	58 Kesimpta (Copaxone) \$3.224 Billion Neurology	59 Calquence (Acalabrutinib) \$3.129 Billion Oncology	60 Lenvima (Lenvatinib) \$3.128 Billion Immunology
61 Lymparza (Olaparib) \$3.072 Billion Oncology	62 Kisqali (Enzalutamide) \$3.033 Billion Oncology	63 Simponi (Simeplumab) \$3.026 Billion Immunology	64 Eriteada (Aripiprazole) \$2.999 Billion Neurology	65 Actemra (Tocilizumab) \$2.913 Billion Oncology	66 Symbicort (Budesonide/Formoterol) \$2.879 Billion Infectious Diseases	67 Dovato (Dolutegravir/Lamivudine) \$2.785 Billion HIV/AIDS	68 Botox Cosmetic (OnabotulinumtoxinA) \$2.720 Billion Dermatology	69 Vyvanse (Lisdexamfetamine) \$2.712 Billion Neurology	70 Brukina (Sutimab) \$2.444 Billion Oncology	71 Soliris (Eculizumab) \$2.588 Billion Hematology	72 Venclexta (Vinorelbine) \$2.583 Billion Oncology	73 Padcev (Enfortumab Vedotin) \$2.534 Billion Oncology	74 Yervoy (Ipilimumab) \$2.530 Billion Oncology	75 ProQuad (MM, Varicella, Rubella, Measles, Mumps, Rubella, and Varicella Virus Vaccine) \$2.465 Billion Infectious Diseases	76 Rexult (Brexipiprazole) \$2.461 Billion Oncology	77 Xgeva (Denosumab) \$2.449 Billion Oncology	78 Beyfortus (Eprex) \$2.367 Billion Infectious Diseases	79 Humalog (Insulin Lispro) \$2.324 Billion Diabetes	80 Ingrezza (Vibegron) \$2.313 Billion Neurology
81 NovoRapid (Insulin Aspart) \$2.508 Billion Diabetes	82 Abilify (Aripiprazole) \$2.268 Billion Neurology	83 Repatha (Evolocumab) \$2.222 Billion Cardiology/Vascular Diseases	84 Nucala (Mepolizumab) \$2.219 Billion Oncology	85 Promacta (Eltrombopag) \$2.216 Billion Oncology	86 Kadcyla (Trastuzumab Emtansine) \$2.201 Billion Oncology	87 Opsumit (Macitentan) \$2.184 Billion Cardiology/Vascular Diseases	88 Reblozyl (Luspatercept) \$2.144 Billion Hematology	89 Cimzia (Certolizumab Pegol) \$2.133 Billion Immunology	90 Otezla (Apremilast) \$2.126 Billion Oncology	91 Descovy (Emtricitabine/Tenofovir Alafenamide) \$2.113 Billion HIV/AIDS	92 Lixiana (Edoxaban) \$2.060 Billion Oncology	93 Tafinlar (Dabrafenib/Trametinib) \$2.058 Billion Oncology	94 Adcetris (Brexitucab Mab Vedotin) \$1.940 Billion Oncology	95 Jakavi (Ruxitinib) \$1.908 Billion Infectious Diseases	96 Phegso (Perfenoxin/Tramadol/Paracetamol) \$1.916 Billion Oncology	97 Remicade (Infliximab) \$1.880 Billion Oncology	98 Benlysta (Belimumab) \$1.853 Billion Infectious Diseases	99 Tepezza (Teprotumumab) \$1.851 Billion Oncology	100 Trajenta (Linagliptin/Vitamin E) \$1.834 Billion Neurology
101 Uptavri (Simeglitin) \$1.817 Billion Cardiology/Vascular Diseases	102 Vekury (Kerastin) \$1.799 Billion Infectious Diseases	103 Erysdi (Risedronate) \$1.796 Billion Neurology	104 Spinraza (Elesclerone) \$1.789 Billion Genetic Diseases	105 Bridion (Sugammadex) \$1.764 Billion Neurology	106 Genovyo (Sunitinib Malate) \$1.742 Billion Infectious Diseases	107 Tysabri (Fingolimod) \$1.715 Billion Neurology	108 Prezista (Darunavir/Cobicistat) \$1.712 Billion HIV/AIDS	109 Creon (Pancrelipase) \$1.711 Billion Anti-Cancer and Diabetes	110 Alecensa (Alectinib) \$1.705 Billion Oncology	111 Fasenra (Benralizumab) \$1.689 Billion Pulmonary/Respiratory Diseases	112 Lantus (Insulin Glargine) \$1.688 Billion Diabetes	113 Austedo (Dehydroepiandrosterone) \$1.689 Billion Neurology	114 Tivicy (Dolutegravir) \$1.679 Billion Infectious Diseases	115 Eventy (Rimegepant) \$1.671 Billion Musculoskeletal	116 Tasigna (Crizotinib) \$1.671 Billion Oncology	117 Triumeq (Abacavir/Dolutegravir/Rilpivirine) \$1.448 Billion Infectious Diseases	118 Kyprolis (Carboplatin) \$1.426 Billion Oncology	119 Tyvaso (Tirofiban) \$1.420 Billion Cardiology/Vascular Diseases	120 Nubeqa (Darolutamide) \$1.403 Billion Oncology
121 Eplura (Sofosbuvir/Velparvir) \$1.576 Billion Infectious Diseases	122 Jynarque (Tolvaptan) \$1.570 Billion Cardiology/Vascular Diseases	123 Yescarta (Axicabtagene Ciloleucel) \$1.570 Billion Oncology	124 Nexgard (Axitinib) \$1.530 Billion Oncology	125 Herceptin (Trastuzumab) \$1.521 Billion Oncology	126 MabThera (Rituximab) \$1.519 Billion Oncology	127 Ilaris (Canakinumab) \$1.509 Billion Immunology	128 Trintellix (Vortioxetine) \$1.508 Billion Oncology	129 Xywav (Co, Mg, K, and Na Oxybates) \$1.473 Billion Oncology	130 Lipitor (Atorvastatin) \$1.468 Billion Cardiology/Vascular Diseases	131 Adempas (Sildenafil) \$1.461 Billion Cardiology/Vascular Diseases	132 Nplate (Rilotumumab) \$1.456 Billion Oncology	133 Takzhryo (Rituximab) \$1.419 Billion Cardiology/Vascular Diseases	134 Dysport (AbobotulinumtoxinA) \$1.400 Billion Oncology	135 Crysita (Ruxitinib) \$1.419 Billion Infectious Diseases	136 Strensiq (Aflibercept) \$1.416 Billion Oncology	137 Pluvicto (Lutetium-177 Vipivotide Tetraxetan) \$1.392 Billion Oncology	138 Tresiba (Insulin Degludec) \$1.373 Billion Diabetes	139 Avastin (Bevacizumab) \$1.358 Billion Oncology	140 Aranesp (Darbepoetin Alfa) \$1.342 Billion Neurology
141 Mirena (Levonorgestrel) \$1.334 Billion Women's Health	142 Januvia (Sitagliptin) \$1.334 Billion Diabetes	143 Brinta (Escitalopram) \$1.333 Billion Cardiology/Vascular Diseases	144 Relvar (Fluticasone Furoate) \$1.327 Billion Pulmonary/Respiratory Diseases	145 ActiVase (Alteplase/Tenecteplase) \$1.324 Billion Cardiology/Vascular Diseases	146 Trodely (Baclofen/Carbamazepine) \$1.315 Billion Oncology	147 Seretide (Salmeterol) \$1.314 Billion Pulmonary/Respiratory Diseases	148 Prograf (Tacrolimus) \$1.311 Billion Infectious Diseases	149 Mavyret (Glecaprevir/Pibrentavir) \$1.311 Billion HIV/AIDS	150 Bilcity (Bilastin) \$1.290 Billion Oncology	151 Ondefsey (Onasemnogene Aesoxatecil Adenosine Triphosphate) \$1.288 Billion Cardiology/Vascular Diseases	152 Sprycel (Sunitinib) \$1.286 Billion Oncology	153 Sandostatin (Octreotide) \$1.279 Billion Cardiology/Vascular Diseases	154 Toujeo (Insulin Glargine) \$1.272 Billion Diabetes	155 Edurant (Bilastin) \$1.272 Billion Oncology	156 Nurtec ODT (Rimegepant) \$1.263 Billion Musculoskeletal	157 Cabenuva (Cabotegravir/Rilpivirine) \$1.260 Billion Infectious Diseases	158 Bexsero (Meningococcal Vaccine) \$1.256 Billion Infectious Diseases	159 Polyv (Patisiran) \$1.234 Billion Hematology	160 Vectibix (Panitumumab) \$1.227 Billion Oncology
161 Tezspire (Tezepelumab) \$1.220 Billion Pulmonary/Respiratory Diseases	162 Libtayo (Cemiplimab) \$1.216 Billion Oncology	163 Zolgensma (Onasemnogene Aesoxatecil Adenosine Triphosphate) \$1.214 Billion Genetic Diseases	164 Lucentis (Ranibizumab) \$1.202 Billion Ophthalmology	165 Spiriva (Vilanterol) \$1.201 Billion Pulmonary/Respiratory Diseases	166 Krytstexa (Pegloticase) \$1.185 Billion Oncology	167 Juvederm (Hyaluronic Acid) \$1.177 Billion Dermatology	168 Xeljanz (Tofacitinib) \$1.168 Billion Immunology	169 Somatuline (Lanreotide) \$1.162 Billion Oncology	170 Betasin (Sibastegron) \$1.159 Billion Oncology	171 Crestor (Rosuvastatin) \$1.153 Billion Cardiology/Vascular Diseases	172 NovoSeven (Recombinant Coagulation Factor VII) \$1.106 Billion Hematology	173 Abraxane (Paclitaxel Protein Bound) \$1.100 Billion Oncology	174 Fabrazyme (Agalsidase Beta) \$1.085 Billion Oncology	175 Spravato (Esketamine) \$1.077 Billion Oncology	176 Zoladex (Goserelin) \$1.068 Billion Oncology	177 Loxoven (Enoxaparin) \$1.018 Billion Infectious Diseases	178 Urelvay (Urokinase) \$1.006 Billion Infectious Diseases	179 Gazyva (Obinutuzumab) \$1.002 Billion Oncology	180 Bretrzi (Budesonide/Cyclosporin/Formoterol) \$978 Million Pulmonary/Respiratory Diseases
181 Inlyta (Vandetanib) \$978 Million Oncology	182 Cyramza (Ramotuzumab) \$973 Million Oncology	183 Gattex (Tegsipal) \$972 Million Gastrointestinal Diseases	184 Epidiolex (Cannabidiol) \$972 Million Neurology	185 Amvuttra (Vutrisiran) \$970 Million Genetic Diseases	186 Tecfidera (Dimethyl Fumarate) \$967 Million Neurology	187 Human Insulin (Human Insulin) \$965 Million Diabetes	188 Lagevrio (Mogroside) \$964 Million Infectious Diseases	189 Carykti (Chlorazepate Acetate) \$963 Million Oncology	190 Neuplan (Ergometrin) \$963 Million Women's Health	191 Saxenda (Liraglutide) \$962 Million Nutritional Deficiency	192 Albumin (Albumin) \$960 Million Immunology	193 Vemlidy (Tenofvir Disoproxil) \$959 Million Infectious Diseases	194 Olumiant (Bardoxiprin) \$957 Million Immunology	195 Linzess (Linzaclopride) \$954 Million Gastrointestinal Diseases	196 Plavix (Clopidogrel) \$947 Million Cardiology/Vascular Diseases	197 Janumet (Sitagliptin/Metformin) \$935 Million Diabetes	198 Opduvalg (Nivolumab/Ipilimumab) \$928 Million Oncology	199 Humulin (Insulin Isophane) \$917 Million Diabetes	200 Engaltis (Goltargol) \$883 Million Neurology

Key: Oncology, Immunology, Infectious Diseases, Neurology, Diabetes, Cardiology/Vascular Diseases, Hematology, Pulmonary/Respiratory Diseases, Genetic Diseases, Anti-Cancer and Diabetes, Ophthalmology, Nutritional Deficiency, Dermatology, Other